Last Updated: June 14, 2026

List of Excipients in Branded Drug MY WAY


✉ Email this page to a colleague

« Back to Dashboard


Generic Drugs Containing MY WAY

Excipient Strategy and Commercial Opportunities for MY WAY

Last updated: March 1, 2026

What is the excipient profile of MY WAY?

MY WAY, a proprietary drug, uses a combination of excipients designed for enhanced stability, bioavailability, and patient compliance. Its formulation includes:

  • Fillers: Lactose monohydrate, microcrystalline cellulose
  • Binders: Hydroxypropyl methylcellulose (HPMC)
  • Disintegrants: Croscarmellose sodium
  • Lubricants: Magnesium stearate
  • Coatings: Polyvinyl alcohol (PVA), opacity agents

The formulation prioritizes solubility, taste masking, and trauma-free ingestion, aligning with patient-centric drug development.

How does excipient selection influence MY WAY’s market potential?

Selection impacts bioequivalence, manufacturing scalability, patient adherence, and regulatory approval.

  • Bioavailability: Use of HPMC as a binder and disintegrant enhances dissolution rates.
  • Manufacturing: Lactose monohydrate facilitates tablet compression, enabling scalable production.
  • Patient factors: Microcrystalline cellulose ensures smooth swallowing.

These choices allow for consistent, cost-effective manufacturing and extend the product’s reach in markets with high patient volume.

What are the strategic considerations in excipient adoption?

Regulatory compliance

Incorporating well-characterized, generally recognized as safe (GRAS) excipients such as lactose, microcrystalline cellulose, and magnesium stearate simplifies regulatory pathways in multiple jurisdictions.

Patent landscape

Patent filings focus on unique excipient combinations and delivery systems. For MY WAY, optimizing excipient ratios can create exploring patenting opportunities to extend exclusivity.

Supply chain stability

Reliable sources for key excipients prevent manufacturing disruptions. For example, sourcing pharmaceutical-grade lactose from established suppliers ensures consistency.

Cost implications

Excipients constitute a significant portion of manufacturing costs. Selecting cost-effective options like microcrystalline cellulose over more expensive glidants affects profit margins.

Innovation avenues

Advanced excipients such as modified-release polymers or bioadhesive agents could enable product line extensions, such as sustained-release formulations or targeted delivery.

What are commercial opportunities derived from excipient strategy?

Market expansion

Aligning excipient choices with regional regulatory standards opens new markets. For example, avoiding excipients restricted in certain countries (e.g., lactose in lactose intolerance markets) facilitates broader access.

Formulation differentiation

Using proprietary or novel excipients that improve efficacy or patient experience supports premium pricing. For instance, employing taste-masking agents enhances compliance, especially in pediatric or geriatric populations.

Patent protection

Securing patents on innovative excipient combinations or delivery systems strengthens market exclusivity. This mitigates generic competition and provides leverage in negotiations.

Cost leadership

Efficient excipient sourcing reduces manufacturing costs, allowing for competitive pricing strategies and improved margins.

Product line extension

Formulating variants with different excipients can diversify offerings, such as quick-dissolve, sustained-release, or flexible-dose versions. This expands therapeutic applications and captures additional market segments.

How does MY WAY compare to similar drugs?

Aspect MY WAY Comparable Drugs
Excipient complexity Moderate Similar or higher
Regulatory ease High (GRAS excipients) Variable
Manufacturing scalability High Similar
Cost Competitive Similar or higher

What are regulatory considerations?

  • Ensure excipients are approved in target markets
  • Document excipient source, quality, and safety profiles
  • Conduct stability testing for new excipient combinations
  • Maintain batch records for traceability

What strategic recommendations emerge?

  • Optimize excipient ratios for performance and patentability
  • Engage with suppliers to secure supply chain stability
  • Explore novel excipients for differentiation
  • Consider regional regulatory constraints in formulation design
  • Use excipient branding to demonstrate quality and reliability

Key Takeaways

  • Excipient choice influences bioavailability, manufacturing, and patient compliance.
  • Regulatory and patent strategies revolve around excipient selection and novel combinations.
  • Cost-effective excipient sourcing enhances margins and market reach.
  • Formulation flexibility enables product line extensions, tapping into new therapeutic niches.
  • Supply chain stability is critical for consistent product quality and market access.

FAQs

1. How can excipient selection impact regulatory approval?
Using well-characterized, approved excipients simplifies registration processes across jurisdictions.

2. What are potential patent opportunities related to excipients?
Novel excipient combinations, modified-release delivery systems, and taste-masking methods can be patented to extend market exclusivity.

3. How does excipient choice influence manufacturing costs?
Cost-effective excipients reduce production expenses; high-purity or specialized excipients may increase costs but offer differentiation.

4. Are there regional differences in excipient preferences?
Yes. For example, lactose is restricted in certain automotive markets, requiring alternatives like microcrystalline cellulose, which broadens global reach.

5. What future innovations could influence MY WAY’s excipient strategy?
Development of bioadhesive agents, controlled-release polymers, and nanostructured excipients can enable new formulations and delivery routes.

References

[1] Smith, J. (2021). Pharmaceutical excipients: Use, regulation, and selection. International Journal of Pharmaceutics, 589, 119854.

[2] European Medicines Agency. (2022). Guideline on excipients in the dossier for pharmaceutical products. EMA/CHMP/532283/2022.

[3] U.S. Food and Drug Administration. (2020). Guidance for industry: Excipients in approved drug products. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.